Bucladesine
Bucladesin · BUCLADESINE · N-(9-beta-D-Ribofura · Cyclic AMP dibutyrate · Dibutyryl cyclic 3',5'-AMP · Dibutyryl 3',5'-Cyclic AMP · CalciuM Dibutyacyladenosine · 3',5'-Cyclic AMP dibutyrate
Identifiers & Physical Properties
| CAS No. | 362-74-3 |
|---|---|
| Molecular formula | C18H24N5O8P |
| Average molar mass | 469.4 g/mol |
| Monoisotopic mass | 469.13624974 g/mol |
| SMILES | CCCC(=O)Nc1ncnc2c1ncn2[C@@H]1O[C@@H]2COP(=O)(O)O[C@H]2[C@H]1OC(=O)CCC |
| InChIKey | CJGYSWNGNKCJSB-YVLZZHOMSA-N |
| PubChem CID | 9687 |
| ChEMBL | CHEMBL485980 |
| ChEBI | CHEBI:50095 |
| EC No. | 206-649-8 |
| DTXSID | DTXSID1040459 |
Chemical & Physical Properties
| XLogP | -0.5 |
|---|---|
| Topological polar surface area | 164 |
| Hydrogen bond donors | 2 |
| Hydrogen bond acceptors | 11 |
| Rotatable bonds | 8 |
| Heavy atoms | 32 |
| Formal charge | 0 |
| Complexity | 759 |
| Collision Cross Section | 215.3 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]210.36 Ų [M+Na]+ [CCS Type: TW214.52 Ų [M+H]+ [CCS Type: TW214.45 Ų [M+K]+ [CCS Type: TW |
| Density | 1.72±0.1 g/cm3(Predicted) |
| Storage conditions | -20°C Freezer |
| Solubility | DMSOMethano |
| pKa (acidity coefficient) | 0.82±0.60(Predicted) |
| Physical state | Solid |
| Color | White |
| FDA UNII | 63X7MBT2LQ |
| ATC code | C01CE04 |
| GHS pictogram | GHS07 |
| Signal word | Warning |
| GHS hazard statements | H302-H315-H320-H335 |
| GHS precautionary statements | P264-P270-P301+P312-P330 |
Safety & Regulations
| Other safety information | IMAP assessments - Adenosine, N-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate) 2'-butanoate: Environment tier I assessmentIMAP assessments - Adenosine, N-(1-oxobutyl)-, cyclic 3',5'-(hydrogen phosphate) 2'-butanoate: Human health tier I assessment |
|---|---|
| Signal word | Warning |
| GHS pictogram | GHS07 |
| GHS hazard statements | H302-H315-H320-H335 |
| GHS precautionary statements | P264-P270-P301+P312-P330 |
Applications & Uses
Description
Bucladesine is a cyclic nucleotide derivative that mimics the action of endogenous CYCLIC AMP and is capable of permeating the cell membrane. It has vasodilator properties and is used as a cardiac stimulant. (From Merck Index, 11th ed)
Uses
Bucladesine is a cell permeable cAMP analog. The compound is used in a wide variety of research applications because it mimics cAMP and can induce normal physiological responses when added to cells in experimental conditions. cAMP is only able to elicit minimal responses in these situations. The neurite outgrowth instigated by bucladesine in cell cultures has been shown to be enhanced by nardosinone.